Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

Pfizer shares currently trade at approximately $23, down 13% year-to-date and significantly below their 2021 peak of around $60. The company experienced extraordinary growth during the COVID-19 ...

Pfizer will end research into treatments for Alzheimer's and Parkinson's disease, resulting in the elimination of 300 positions at the company's Massachusetts facilities in Andover and Cambridge ...